Jubilant Ingrevia Q2 FY27: Revenue ₹1,394 Crore, PAT Surges 61%, ZettaOne Stake Acquired

The Quick Take

• Jubilant Ingrevia reported Q2 FY27 revenue of ₹1,394 crore and a 61% surge in profit after tax.
• The company also announced acquisition of a stake in ZettaOne, signalling diversification into new technology or specialty areas.
• Strong earnings across specialty chemicals and life sciences segments drove the double-digit growth in profitability.

Jubilant Ingrevia, one of India's leading integrated specialty chemicals and nutrition ingredients companies, reported a significant earnings turnaround in Q2 FY27 with revenue of ₹1,394 crore and a 61% year-on-year surge in profit after tax. The performance reflects a recovery in specialty chemicals margins following a period of inventory destocking by global pharma and agrochemical customers, alongside volume gains in the company's life sciences ingredients and nutrition divisions that supply multinational consumer health brands.

The accompanying ZettaOne stake acquisition adds strategic texture to Jubilant Ingrevia's growth narrative, potentially signaling an expansion into specialty tech-enabled chemistry, contract manufacturing for high-value molecules, or adjacent life sciences sectors where digitalization of formulation processes is creating new market opportunities. India's specialty chemicals sector has been attracting significant strategic attention as global supply chain diversification away from China accelerates, and Jubilant's ability to couple strong organic growth with targeted acquisitions positions it well against peers like SRF, Aarti Industries, and PI Industries.

The forward catalyst is Q3 FY27 guidance on pricing recovery in specialty chemicals — the key variable determining whether the PAT improvement is structural or represents a one-quarter catch-up. Watch global pharma capex plans and crop protection chemical inventory cycles, both of which drive Jubilant's order book. The macro variable is China's specialty chemicals export competitiveness: any further Chinese government support for its chemicals industry would compress the margin uplift Jubilant and Indian peers are capturing from redirected global procurement.

Synthesized from 1 source.